Pfizer signs licensing deal for T-cell platforms, signaling industry interest
1 report, 1 independent
Updated 18:45
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer announced an exclusive licensing agreement with Starna Therapeutics. The deal covers three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs focused on treating autoimmune diseases. Starna Therapeutics will receive an upfront payment of $330 million and is eligible for up to $2.3 billion in development and commercial rights.
From manilatimes.net
Why it matters
The commitment highlights significant industry interest in next-generation engineered T-cell platforms. Such large licensing agreements validate the specialized therapeutics sector and the market for advanced cellular immunotherapy.
From manilatimes.net
Who's involved
- PfizerSigned the exclusive licensing agreement with Starna Therapeutics for CAR-T programs.
Keep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation